Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935718 | 1.00 | CYP2A6 (0.52) | CYP2A6CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL28428414 | 0.74 | CHRM2 (0.55) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL24777358 | 0.73 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL8275384 | 0.71 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL14811086 | 0.71 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL18660627 | 0.71 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL4723565 | 0.71 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2913826 | 0.71 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL14377332 | 0.71 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL24776908 | 0.71 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102712653-B | Isosorbide-5-Nitrae-the dihydrogen pyridine derivative of furopyridyl-replacement and using method thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-21 | — | — | CN | claimed |
| US-20260035358-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-02-05 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-102712653-B | Isosorbide-5-Nitrae-the dihydrogen pyridine derivative of furopyridyl-replacement and using method thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-21 | — | — | CN | disclosed |
| WO-2011109551-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-7470691-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-7235661-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-7057042-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | disclosed |
| WO-2003101994-A1 | FUSED BICYCLIC AROMATIC COMPOUNDS THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | CYP2A6 4425/4885CHRNB2 4257/4885CHRNA4 4770/4885 |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | CYP2A6 615/4885CHRNB2 715/4885CHRNA4 866/4885 |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | CYP19A1, CYP17A1, HSD17B11 | CYP2A6 431/4885CHRNB2 595/4885CHRNA4 986/4885 |
| US-20260035358-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | CRBN, WEE1, WEE2 | CYP2A6 4605/4885CHRNB2 563/4885CHRNA4 808/4885 |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, DDC | CYP2A6 461/4885CHRNB2 580/4885CHRNA4 1072/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP2A6 1010/4885CHRNB2 388/4885CHRNA4 459/4885 |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | CYP2A6 615/4885CHRNB2 715/4885CHRNA4 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.